FOP Treatment Advances and Market Rollout

Takeda and Dr Reddy’s to Bring Qdenga Dengue Vaccine to India in H1 2027

Takeda Pharmaceutical Company and Dr Reddy’s Laboratories signed a distribution agreement for Takeda’s dengue vaccine Qdenga (per thehindu.com). The companies said the vaccine, which the Central Drugs Standard Control Organisation authorised in July 2026 for ages 4–60, is anticipated to become available in India in the first half of 2027 subject to completion of local processes (per thehindu.com).

Insilico’s AI-designed drug rentosertib begins China Phase 3 after trial shows age-reversal signal

Insilico Medicine announced that rentosertib, an AI-discovered therapy for idiopathic pulmonary fibrosis, has entered Phase 3 trials in China (per Fortune). A Sept. 7 Nature Biotechnology paper reported some patients' blood samples showed signs of reversed biological age, though Insilico co-CEO Feng Ren warned the signal is small and may not persist (per Fortune).

FDA approves Fayuvi, first gene therapy for Sanfilippo A by Ultragenyx

The Food and Drug Administration approved Fayuvi, a gene therapy developed by Ultragenyx, as the first drug specifically for Sanfilippo syndrome type A (per statnews). Ultragenyx has not released a price, and patient advocates said the approval gives families new hope and a treatment option (per statnews).

Congress says NSUI routs ABVP in Garhwal Central University student union polls

The Congress said the NSUI won the student union elections held on the Pauri campus of Hemvati Nandan Bahuguna Garhwal Central University, and that the ABVP was comprehensively defeated (per thehindu.com). Congress general secretary K.C. Venugopal framed the result as evidence that Uttarakhand is fed up with the BJP's "anti-people" policies and "destruction," presenting the outcome as a rebuke of the state ruling party (per thehindu.com).

Scholar Rock's Isembyld wins FDA approval as first drug to target SMA muscle loss, improves young patients' motor skills

Scholar Rock won FDA approval for Isembyld, the first therapy specifically approved to target muscle loss in spinal muscular atrophy (per Stat). A late-stage trial showed Isembyld improved motor skills in young patients versus placebo, and the FDA cleared it for adults and children 2 years and older on SMN2-targeting therapies (per Stat).

Roivant’s mosliciguat cut pulmonary vascular resistance 56% in 16-week Phase 2 study

Roivant said mosliciguat reduced pulmonary vascular resistance by 56% versus placebo in a 16-week Phase 2 study. The trial also met key secondary endpoints — a 35-meter placebo-adjusted six-minute walk improvement and a 53% NT-proBNP reduction — which Roivant said could advance treatment and strengthen its finances.

Regeneron's Pasatru wins FDA approval after trial cut new bone formation for FOP patients

Regeneron Pharmaceuticals won U.S. Food and Drug Administration approval for Pasatru to treat fibrodysplasia ossificans progressiva (FOP) (per STAT). The approval is being called the capstone of a three-decade effort and investigators say the drug 'almost completely stops the new [bone] forming,' offering hope that patients can maintain mobility and possibly live longer (per STAT).